Spire Healthcare Group plc (SPI), one of the UK's leading independent hospital operators, has confirmed that the FCA regulatory condition for its recommended acquisition by Tulip UK Bidco Limited has been satisfied as of 19 November 2026. The deal, first announced on 5 September 2026, will see a consortium including funds managed by Toscafund Asset Management, THCP Advisory, and Ares Management acquire Spire's entire issued ordinary share capital. With shareholder approval already secured at meetings held on 30 October 2026, the transaction is now progressing towards a Court Hearing scheduled for 3 December 2026.

Key Points

  • Spire Healthcare Group plc (SPI) — UK-listed private hospital group
  • FCA regulatory condition for the Tulip UK Bidco acquisition satisfied on 19 November 2026
  • Court Hearing scheduled for 3 December 2026; Effective Date expected to be 7 December 2026
  • Investors should watch for Court sanction and any timetable changes announced via a Regulatory Information Service

FCA Approval Clears Major Hurdle for Spire Healthcare Scheme of Arrangement

Spire Healthcare and Bidco confirmed on 20 November 2026 that the FCA Regulatory Condition, as set out in the scheme document published on 29 September 2026, was formally satisfied on 19 November 2026. This clears one of the principal regulatory hurdles facing the acquisition, which is being implemented via a Court-approved scheme of arrangement under Part 26 of the Companies Act 2006. Spire operates private hospitals across the United Kingdom and generates revenue primarily through self-pay, insured, and NHS-funded patient treatments. The company did not disclose the financial terms of the offer in this particular update.

Spire Shareholder Approval Already Secured at 30 October 2026 Court Meeting and General Meeting

The announcement states that Scheme Shareholders approved the transaction at the Court Meeting held on 30 October 2026, with the requisite majority also passing the implementing resolution at the General Meeting held on the same date. These milestones mean the transaction has now cleared both its shareholder and FCA regulatory conditions. The remaining conditions include sanction of the Scheme by the Court at the 3 December 2026 hearing, and delivery of the Court Order to the Registrar of Companies, before the Effective Date of 7 December 2026 can be confirmed.

Spire Shares to Be Suspended by 7.30 a.m. on 7 December 2026 and Delisted by 8 December 2026

Subject to Court sanction, the last day of dealings in Spire Shares on the Main Market of the London Stock Exchange is expected to be 4 December 2026, with the Scheme Record Time set at 6.00 p.m. that day. Trading will be suspended by 7.30 a.m. on 7 December 2026, and cancellation of the listing and admission to trading is expected by 8.00 a.m. on 8 December 2026. Investors holding shares in certificated form who wish to elect for the Alternative Offer must submit their Form of Election by 1.00 p.m. on 2 December 2026.

Alternative Offer Election Deadlines and KYC Requirements for Eligible Spire Shareholders

Eligible Scheme Shareholders wishing to elect for the Alternative Offer — which involves rollover securities rather than cash — must submit KYC information in a form satisfactory to Bidco by 1.00 p.m. on 30 November 2026. The Election Return Time for CREST holders and certificated shareholders is 1.00 p.m. on 2 December 2026. Shareholders who do not submit an election will automatically receive the cash consideration. The latest date by which the entire Scheme must be implemented remains 11.59 p.m. on 4 March 2027, extendable by agreement between Spire and Bidco with Panel consent.